EUVIMEDAtrasti EUVIMED
KohortenstudieOpen access · CC BY 4.0

Pharmaceutical policy and off‐label prescribing in pregnancy: A population‐based historical cohort study analyzing inequality in access to antiemetics within Australia's Pharmaceutical Benefits Scheme

Hannah Jackson iD, Luke Grzeskowiak iD, Joanne Enticott iD, Sarah Wise iD, Emily Callander iD

Acta Obstetricia et Gynecologica Scandinavica · 2026-09 · 105 (9) · 1789-1799

DOI: 10.1111/aogs.70283 ↗

At a glance

Kohortenstudie in Acta Obstetricia et Gynecologica Scandinavica, published online on 2026-06-11. Written by Hannah Jackson and 4 co-authors. Institution: Faculty of Health, School of Public Health, University of Technology Sydney, Sydney, New South Wales, Australia. Major MEDLINE topics: Antiemetics, Off-Label Use, Healthcare Disparities, Health Services Accessibility. 34 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Health and Medical Research Council, Channel 7 Children's Research Foundation, Australian Government Research Training Program Stipend.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Introduction

Nausea and vomiting in pregnancy is highly prevalent and can significantly impact pregnant women's quality of life. Despite this, access to effective pharmacotherapies can be constrained by stringent regulatory controls and socioeconomic barriers. The objective of this study was to examine the socioeconomic distribution of antiemetics (metoclopramide, ondansetron, and prochlorperazine) dispensed to pregnant women through Australia's publicly subsidized Pharmaceutical Benefits Scheme. Material and Methods We used the Maternity1000 linked administrative dataset to characterize antiemetics dispensed during 297 630 pregnancies in Queensland, Australia (July 2013 to June 2018). Using a population‐based historical cohort study design, we analyzed dispensing volume, prevalence, and government expenditure across socioeconomic quintiles, with socioeconomic disadvantage defined using the Australian Bureau of Statistics' Index of Relative Socioeconomic Disadvantage. Inequalities in medication access and public expenditure were assessed using concentration indices (C) and concentration curves.

Results

Off‐label ondansetron dispensings for nausea and vomiting in pregnancy (i.e., use outside Therapeutic Goods Administration‐approved indications and not subsidized under the Pharmaceutical Benefits Scheme) accounted for the largest share of public expenditure (53.5%), followed by metoclopramide (45.2%) and prochlorperazine (1.3%). Across all three antiemetics, prevalence was highest among women in the most socioeconomically disadvantaged quintiles and declined progressively across the two least disadvantaged groups. Small pro‐poor inequalities in access (C < −0.10) and moderate pro‐poor inequalities in public expenditure (C > −0.25) were observed across all antiemetics. (Medication access: C metoclopramide = −0.07, 95% CI (−0.080 to −0.068); C ondansetron = −0.09, 95% CI (−0.114 to −0.075); C prochlorperazine = −0.08, 95% CI (−0.109 to −0.045). Government expenditure: C metoclopramide = −0.30, 95% CI (−0.316 to −0.285); C ondansetron = −0.25, 95% CI (−0.297 to −0.198); C prochlorperazine = −0.28, 95% CI (−0.350 to −0.205)).

Conclusions

Off‐label ondansetron access accounted for the majority of public expenditure on antiemetics dispensed during pregnancy, revealing a disconnect between health policy, clinical practice, public expenditure, and pregnant women's needs. While pro‐poor access and public subsidies for antiemetics align with the equity elements embedded in the design of the Pharmaceutical Benefits Scheme, they may also be reflective of inequitable access to other unsubsidized, guideline‐recommended pharmacotherapies for nausea and vomiting in pregnancy.

Subjects

MeSH terms (MEDLINE)

AntiemeticsOff-Label UseHealthcare DisparitiesHealth Services AccessibilityHumansFemalePregnancyAdultCohort StudiesQueenslandOndansetronAustraliaSocioeconomic Disparities in HealthMetoclopramideSocioeconomic FactorsPractice Patterns, Physicians'

Author keywords

costs and cost analysisdatasetequitymaternal healthmedicationobstetric

Substances

AntiemeticsOndansetronMetoclopramide

Authors and institutions

  • Faculty of Health, School of Public Health, University of Technology Sydney, Sydney, New South Wales, Australia.
  • College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
  • SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
  • Monash Centre for Health Research and Implementation (MCHRI), Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.

ORCID profiles: Hannah Jackson, Luke Grzeskowiak, Joanne Enticott, Sarah Wise, Emily Callander

Funding

  • National Health and Medical Research Council
  • Channel 7 Children's Research Foundation
  • Australian Government Research Training Program Stipend

Cite

APA

Jackson, H., Grzeskowiak, L., Enticott, J., Wise, S., & Callander, E. (2026). Pharmaceutical policy and off‐label prescribing in pregnancy: A population‐based historical cohort study analyzing inequality in access to antiemetics within Australia's Pharmaceutical Benefits Scheme. Acta Obstetricia et Gynecologica Scandinavica, 105(9), 1789-1799. https://doi.org/10.1111/aogs.70283

Vancouver

Jackson H, Grzeskowiak L, Enticott J, Wise S, Callander E. Pharmaceutical policy and off‐label prescribing in pregnancy: A population‐based historical cohort study analyzing inequality in access to antiemetics within Australia's Pharmaceutical Benefits Scheme. Acta Obstetricia et Gynecologica Scandinavica. 2026;105(9):1789-1799. doi:10.1111/aogs.70283

BibTeX
@article{Jackson2026,
  author = {Jackson, Hannah and Grzeskowiak, Luke and Enticott, Joanne and Wise, Sarah and Callander, Emily},
  title = {Pharmaceutical policy and off‐label prescribing in pregnancy: A population‐based historical cohort study analyzing inequality in access to antiemetics within Australia's Pharmaceutical Benefits Scheme},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2026},
  volume = {105},
  number = {9},
  pages = {1789--1799},
  doi = {10.1111/aogs.70283}
}
Start for free →